Drugs / S-3304
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00033215 | Nov 2001 → Feb 2003 | cancer | Shionogi | Completed | No outcome recorded |
| Phase 1 | NCT00033566 | Oct 2001 → Dec 2002 | cancer of unknown primary site | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00078390 | Feb 2003 → Sep 2006 | non-small cell lung carcinoma | Shionogi | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S-3304 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00033566 ↗ |
| Action | Inhibit | “S-3304 is a potent, orally active, noncytotoxic inhibitor of MMPs, primarily MMP-2 and MMP-9” PMID 17404091 ↗ Apr 2007 |
| Modality | Small molecule | — CHEMBL297792 ↗ |
| Route | Oral | “S-3304 is a potent, orally active, noncytotoxic inhibitor of MMPs” PMID 17404091 ↗ Apr 2007 |